- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940075
SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .
November 13, 2026 updated by: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension.
This phase II clinical trial, involving multiple subcutaneous injections, aimed to evaluate the efficacy, safety, pharmacokinetic (PK), PD, and immunogenicity characteristics of SYH2062 injection in patients with mild to moderate essential hypertension.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
360
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Trials Information Group officer
- Phone Number: +8631169085587
- Email: ctr-contact@cspc.cn
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 101118
- Recruiting
- Beijing Anzhen Hospital Affiliated to Capital Medical University
-
Contact:
- jun cai, PhD
- Phone Number: 13810615602
- Email: caijun7879@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥18 years of age, male or female at the time of signing the ICF;
- Body mass index range of 18.0 ≤ BMI ≤ 37.5 kg/m2;
- Untreated / Currently receiving 1-2 antihypertensive medications;
- Blood pressure in the clinic during the screening period or before randomization meets 130 ≤ SBP < 170 mmHg, DBP < 110 mmHg;
- Ambulatory blood pressure during the screening period meets 130 mmHg ≤ mSBP;
- Participants are able to communicate well with the researchers and complete the trial according to the protocol.
Exclusion Criteria:
- Allergy to any component of the study drug; or a clinically significant history of severe allergy;
- Hypertension and secondary hypertension in special populations;
- History of orthostatic hypotension;
- Severe cardiovascular or cerebrovascular disease within 6 months prior to screening;
- History of severe arrhythmia within 6 months prior to screening;
- Malignant tumor within 5 years prior to screening, except for tumors expected to be curable after treatment (such as completely excised basal cell carcinoma or squamous cell carcinoma of the skin, etc.)
- Underwent major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period;
- When screening, ALT and AST > 2 times the upper limit of normal, or total bilirubin and direct bilirubin > 1.5 times the upper limit of normal;
- Estimated eGFR at screening < 30 mL/min/1.73 m2;
- Serum potassium level at screening > 5 mmol/L.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo Injection |
|
Experimental: SYH 2062 Injection
|
SYH 2062 Injection |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in 24-hour ambulatory blood pressure (mSBP) from baseline at week 12 post-treatment
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 11, 2026
Primary Completion (Estimated)
January 31, 2027
Study Completion (Estimated)
October 31, 2027
Study Registration Dates
First Submitted
July 30, 2026
First Submitted That Met QC Criteria
November 13, 2026
First Posted (Actual)
November 16, 2026
Study Record Updates
Last Update Posted (Actual)
November 16, 2026
Last Update Submitted That Met QC Criteria
November 13, 2026
Last Verified
November 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- SYH2062-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.